Beyond Air, Inc. (XAIR)
NASDAQ: XAIR · Real-Time Price · USD
0.49295
+0.0059 (1.20%)
Apr 28, 2026, 11:14 AM EDT - Market open
Beyond Air Revenue
Beyond Air had revenue of $2.19M in the quarter ending December 31, 2025, with 104.66% growth. This brings the company's revenue in the last twelve months to $6.92M, up 129.04% year-over-year. In the fiscal year ending March 31, 2025, Beyond Air had annual revenue of $3.71M.
Revenue (ttm)
$6.92M
Revenue Growth
+129.04%
P/S Ratio
0.75
Revenue / Employee
$113,508
Employees
61
Market Cap
5.19M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.71M | - | - |
| Dec 31, 2024 | 3.71M | 2.55M | 219.67% |
| Mar 31, 2024 | 1.16M | - | - |
| Dec 31, 2023 | 1.16M | - | - |
| Mar 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Mar 31, 2021 | 873.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Mar 31, 2020 | 1.39M | - | - |
| Dec 31, 2019 | - | - | - |
| Mar 31, 2019 | 7.72M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Jun 30, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| INVO Fertility | 6.94M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 3.58M |
| Co-Diagnostics | 622.49K |
| iTonic Holdings | 523.03K |
| Tivic Health Systems | 482.00K |
| Nexalin Technology | 301.65K |
| HeartSciences | 8.67K |
XAIR News
- 8 days ago - Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 - GlobeNewsWire
- 13 days ago - Beyond Air to Participate in the D. Boral Capital Global Conference 2026 - GlobeNewsWire
- 5 weeks ago - Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial - GlobeNewsWire
- 6 weeks ago - Beyond Air Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 2 months ago - Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections - GlobeNewsWire
- 2 months ago - Beyond Air Earnings Call Transcript: Q3 2026 - Transcripts
- 2 months ago - Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences - GlobeNewsWire